Cardax, Inc. (CDXI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCardax, Inc. (CDXI) trades at $0.0001. Cardax, Inc. is a biopharmaceutical company focused on developing and commercializing dietary supplements for inflammatory health and pharmaceutical candidates for chronic diseases driven by inflammation and oxidative stress. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for CDXI: CDXI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Cardax, Inc. (CDXI) Healthcare & Pipeline Overview
Cardax, Inc. is a biopharmaceutical company focused on inflammatory health, developing dietary supplements like ZanthoSyn for enhanced absorption and purity, alongside pharmaceutical candidates CDX-101 for severe hypertriglyceridemia and CDX-301 for macular degeneration. The Honolulu-based firm leverages astaxanthin and zeaxanthin research, primarily selling its supplement via e-commerce and wholesale channels.
What Is the Investment Thesis for CDXI?
Cardax, Inc. presents an investment thesis centered on its dual-pronged approach to inflammatory health, combining a commercialized dietary supplement with a pipeline of pharmaceutical candidates. The company's ZanthoSyn supplement, leveraging enhanced astaxanthin absorption, provides an existing revenue stream, albeit with a negative profit margin of -938.0% and a gross margin of 63.6%. The primary value drivers are the advanced development of CDX-101 for severe hypertriglyceridemia and CDX-301 for macular degeneration. These pharmaceutical candidates target large and growing markets with significant unmet needs, offering substantial upside potential upon successful clinical development and regulatory approval. The company's focus on natural compounds like astaxanthin and zeaxanthin, known for their anti-inflammatory and antioxidant properties, underpins its scientific differentiation. However, the early-stage nature of its pharmaceutical pipeline, coupled with the inherent risks of drug development and the company's current financial performance, necessitates careful consideration of its long-term viability and capital requirements for clinical trials.
Based on FMP financials and quantitative analysis
CDXI Key Highlights
Cardax, Inc. operates with a gross margin of 63.6%, indicating efficient cost management relative to its revenue from product sales.
- The company currently has a negative profit margin of -938.0%, reflecting significant investment in research and development and operational costs relative to its current revenue base.
- Cardax is developing two pharmaceutical candidates, CDX-101 for severe hypertriglyceridemia and CDX-301 for macular degeneration, targeting substantial therapeutic markets.
- The company commercializes ZanthoSyn, a dietary supplement for inflammatory health, primarily through e-commerce and wholesale channels.
- With a market capitalization of $0.00 billion, Cardax, Inc. is a micro-cap entity, indicative of its early-stage development and market presence.
Who Are CDXI's Competitors?
CDXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.79 | +0.41% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.52 | +0.67% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.58 | -2.28% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.67 | -1.29% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.73 | -2.33% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.48 | +3.08% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.28 | +1.18% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CDXI's Key Strengths?
Commercialized dietary supplement (ZanthoSyn) providing an existing revenue stream with a 63.6% gross margin.
- Pipeline of pharmaceutical candidates (CDX-101, CDX-301) targeting significant medical needs in large markets.
- Focus on natural compounds (astaxanthin, zeaxanthin) with established health benefits, appealing to both supplement and pharmaceutical segments.
- Direct-to-consumer e-commerce channel for ZanthoSyn allows for direct customer engagement and potentially higher margins.
What Are CDXI's Weaknesses?
Significant negative profit margin of -938.0%, indicating substantial operational losses.
- Small employee base of 10, which may limit the scope and speed of pharmaceutical development.
- Early-stage nature of pharmaceutical pipeline (CDX-101, CDX-301) entails high development risk and long timelines.
- Reliance on e-commerce and wholesale for ZanthoSyn sales, which can be competitive and require continuous marketing investment.
What Are the Key Risks for CDXI?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin (-938.0%) indicates substantial ongoing losses, raising concerns about long-term financial sustainability without additional capital infusions.
- High risk of clinical trial failures for CDX-101 and CDX-301, which would severely impact the company's pharmaceutical pipeline and future revenue potential.
- Intense competition in both the dietary supplement market for ZanthoSyn and the pharmaceutical markets targeted by CDX-101 and CDX-301.
- Regulatory hurdles and lengthy approval processes for pharmaceutical candidates, which can delay market entry and incur significant costs.
- Challenges associated with trading on the 'OTC Other' tier, including low liquidity, limited disclosure, and potential for high volatility, impacting investor confidence and share price stability.
What Threats Does CDXI Face?
- Intense competition in both the dietary supplement and pharmaceutical markets.
- High costs and long timelines associated with pharmaceutical research, development, and regulatory approval.
- Potential for clinical trial failures or adverse regulatory decisions for CDX-101 and CDX-301.
- Dependence on consumer trends and scientific validation for the continued market acceptance of astaxanthin and zeaxanthin products.
What Are CDXI's Competitive Advantages?
- Proprietary formulation of ZanthoSyn offering enhanced astaxanthin absorption and purity, differentiating it in the supplement market.
- Specialized focus on astaxanthin and zeaxanthin, building expertise and potential intellectual property in these compounds.
- Dual strategy of commercialized supplements and pharmaceutical pipeline, offering diversified potential revenue streams.
- Targeting specific, high-value pharmaceutical indications like severe hypertriglyceridemia and macular degeneration with novel candidates.
What Does CDXI Do?
Cardax, Inc., headquartered in Honolulu, Hawaii, operates as a biopharmaceutical company dedicated to addressing inflammatory health and chronic diseases linked to inflammation and oxidative stress. The company's strategic approach encompasses both the commercialization of dietary supplements and the development of pharmaceutical candidates. Its flagship dietary supplement, ZanthoSyn, is formulated to support inflammatory health and longevity, distinguishing itself through enhanced absorption and purity of astaxanthin. This product is primarily distributed through e-commerce platforms and established wholesale channels, reaching consumers seeking natural health solutions. Beyond its commercialized supplement, Cardax maintains a robust pharmaceutical pipeline targeting significant unmet medical needs. A key asset in development is CDX-101, an astaxanthin-based pharmaceutical candidate specifically designed for cardiovascular inflammation and dyslipidemia, with a primary indication focus on severe hypertriglyceridemia. This condition represents a substantial market given its prevalence and associated cardiovascular risks. Complementing this, the company is also advancing CDX-301, a zeaxanthin pharmaceutical candidate aimed at treating macular degeneration, a leading cause of vision loss globally. Cardax's dual strategy allows it to generate revenue from its supplement business while simultaneously pursuing the higher-value, longer-term potential of prescription pharmaceuticals. The company's foundation rests on scientific research into the therapeutic properties of natural compounds like astaxanthin and zeaxanthin, positioning it within the innovative segment of the biotechnology industry.
What Products and Services Does CDXI Offer?
- Develops and commercializes dietary supplements for inflammatory health.
- Offers ZanthoSyn, an astaxanthin-based inflammatory supplement with enhanced absorption and purity.
- Sells ZanthoSyn primarily through e-commerce platforms and wholesale channels.
- Develops CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia.
- Targets severe hypertriglyceridemia as a primary indication for CDX-101.
- Develops CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration.
- Focuses on chronic diseases driven by inflammation and oxidative stress.
How Does CDXI Make Money?
- Generates revenue from the direct-to-consumer sales of ZanthoSyn via its e-commerce platform.
- Earns revenue through wholesale distribution of ZanthoSyn to retailers or other distributors.
- Invests in research and development for pharmaceutical candidates (CDX-101, CDX-301) with the aim of future licensing or commercialization revenue.
- Leverages intellectual property related to astaxanthin and zeaxanthin formulations and applications.
What Industry Does CDXI Operate In?
Cardax, Inc. operates within the dynamic and innovation-driven Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development efforts aimed at discovering, developing, and commercializing novel biological products and processes. Cardax's focus on inflammatory health and chronic diseases aligns with a significant global health challenge, as inflammation is implicated in numerous conditions from cardiovascular disease to age-related macular degeneration. The market for dietary supplements, particularly those with scientifically backed ingredients like astaxanthin, is experiencing steady growth driven by increasing consumer awareness of preventative health. Simultaneously, the pharmaceutical segment targeting cardiovascular and ophthalmological conditions represents multi-billion dollar markets, with a constant demand for more effective and safer therapies. Cardax positions itself by leveraging natural compounds for both consumer health products and potential prescription drugs, navigating a competitive landscape that includes both large pharmaceutical companies and specialized biotech firms, as well as a fragmented dietary supplement market.
Who Are CDXI's Key Customers?
- Individual consumers seeking dietary supplements for inflammatory health and longevity, primarily through online channels.
- Wholesale partners and distributors who then sell ZanthoSyn to their own customer bases.
- Future patients with severe hypertriglyceridemia, pending regulatory approval of CDX-101.
- Future patients suffering from macular degeneration, pending regulatory approval of CDX-301.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Cardax, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Honolulu, US. The company is led by CEO David G. Watumull. CDXI has traded publicly since 2013.
Financial Health
Cardax, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
4 transactions · 2 purchases, 0 sales, 2 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
CDXI Financials
CDXI Latest News
No recent news available for CDXI.
CDXI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CDXI.
Price Targets
Wall Street price target analysis for CDXI.
CDXI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CDXI; grades run from A+ (80-100) to F (below 30).
Leadership: David G. Watumull
CEO
David G. Watumull serves as the CEO of Cardax, Inc., leading a team of 10 employees in the company's biopharmaceutical endeavors. His leadership is central to the company's strategy of developing and commercializing dietary supplements for inflammatory health while simultaneously advancing pharmaceutical candidates for chronic diseases.
Track Record: Under David G. Watumull's leadership, Cardax, Inc. has continued to develop and commercialize its ZanthoSyn inflammatory supplement, establishing its presence in the e-commerce and wholesale channels. He has overseen the ongoing development of key pharmaceutical candidates, CDX-101 for severe hypertriglyceridemia and CDX-301 for macular degeneration, guiding the company's strategic focus on these high-potential therapeutic areas. His tenure is marked by the company's commitment to leveraging astaxanthin and zeaxanthin research for both consumer and prescription markets.
CDXI OTC Market Information
Cardax, Inc. trades on the OTC market under the 'OTC Other' tier. This tier is for companies that do not qualify for OTCQX or OTCQB, or choose not to provide the required disclosure. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, corporate governance, and minimum share prices, 'OTC Other' companies have minimal reporting standards. This can result in limited publicly available information and less regulatory oversight compared to higher OTC tiers, potentially increasing investment risk.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means investors may lack critical financial and operational data necessary for thorough due diligence.
- Low Liquidity: Trading on the 'OTC Other' tier often results in very low trading volumes and wide bid-ask spreads, making it challenging to buy or sell shares.
- Increased Volatility: Low liquidity and limited information can contribute to higher price volatility and susceptibility to market manipulation.
- Regulatory Scrutiny: Companies on lower OTC tiers face less stringent regulatory oversight compared to major exchanges, potentially exposing investors to greater risks.
- Difficulty in Valuation: Lack of consistent and comprehensive financial reporting makes it challenging to accurately assess the company's intrinsic value.
- Verify any available financial statements directly from the company or third-party aggregators, despite 'Unknown' status.
- Research the company's management team and their track record beyond what is publicly stated.
- Investigate the competitive landscape for ZanthoSyn and its pharmaceutical pipeline candidates.
- Assess the scientific validity and market potential of astaxanthin and zeaxanthin for targeted indications.
- Understand the regulatory pathway and associated risks for CDX-101 and CDX-301.
- Review any news releases or corporate communications for updates on operations and financials.
- Consider the company's capital structure and potential need for future financing, which could be dilutive.
- Active development pipeline with specific pharmaceutical candidates (CDX-101, CDX-301) targeting defined medical conditions.
- Commercialized dietary supplement (ZanthoSyn) with an established e-commerce and wholesale presence.
- Headquartered in Honolulu, Hawaii, indicating a physical operational base.
- Identified CEO, David G. Watumull, providing clear leadership structure.
Common Questions About CDXI (Healthcare)
What are the main risks associated with an investment in Cardax, Inc.?
Investing in Cardax, Inc. carries several notable risks. Financially, the company operates with a significant negative profit margin of -938.0%, indicating substantial losses relative to its revenue, which raises concerns about its long-term financial stability and potential need for future capital.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The 'Unknown' disclosure status for OTC trading limits the depth of financial analysis.